This is a summary. To read the whole story subscribe to BostonGlobe.com
WASHINGTON — The Food and Drug Administration on Wednesday approved a new diabetes drug from Bristol-Myers Squibb and AstraZeneca that uses a novel approach to reduce blood sugar.
Farxiga is a once-a-day tablet designed to help diabetes patients eliminate excess sugar via their urine. That differs from older drugs that decrease the amount of sugar absorbed from food and stored in the liver.
The drug is the second product approved in the United States from the new class of medicines known as SGLT2 drugs. In March the FDA approved Johnson & Johnson’s Invokana, which also works by eliminating excess sugar through patients’ urine.